BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint
Shots: The company’s P-III (CheckMate -8HW) study met the dual 1EP of PFS in...
Shots: The company’s P-III (CheckMate -8HW) study met the dual 1EP of PFS in...
Shots: The first patient was dosed in the P-II (ADVANTA) trial evaluating the safe...
Shots: Merck has halted its P-III (KEYLYNK-008) study, as suggested by an independ...
Shots: The P-III (IMROZ) clinical trial evaluates Sarclisa (10mg/kg, IV, qw) + VRd...
Shots: The P-III (EVOLUTION) clinical trials incl. (evolutionRMS 1) & (evoluti...
Shots: The P-III (INAVO120) clinical trial evaluates the safety & efficacy of...
Incisive News in 3 Shots.